News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
A surge in UK cell therapy production last year means available manufacturing capacity has declined considerably according to a report by Cell Therapy Catapult.
Hemispherx Biopharma has signed extended US distribution agreements as part of efforts to relaunch Alferon N Injection, a genital wart treatment it pulled in 2008 after production costs soared.
Phage therapy developer AmpliBphi Biosciences has been cleared to list on the New York Stock Exchange’s MKT market.